BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38377004)

  • 1. Proteogenomic characterization of primary colorectal cancer and metastatic progression identifies proteome-based subtypes and signatures.
    Tanaka A; Ogawa M; Zhou Y; Namba K; Hendrickson RC; Miele MM; Li Z; Klimstra DS; Buckley PG; Gulcher J; Wang JY; Roehrl MHA
    Cell Rep; 2024 Feb; 43(2):113810. PubMed ID: 38377004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
    Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM
    Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways.
    Zhang Y; Chen F; Chandrashekar DS; Varambally S; Creighton CJ
    Nat Commun; 2022 May; 13(1):2669. PubMed ID: 35562349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated multi-omics characterization of KRAS mutant colorectal cancer.
    Chong W; Zhu X; Ren H; Ye C; Xu K; Wang Z; Jia S; Shang L; Li L; Chen H
    Theranostics; 2022; 12(11):5138-5154. PubMed ID: 35836817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.
    Tong Y; Sun M; Chen L; Wang Y; Li Y; Li L; Zhang X; Cai Y; Qie J; Pang Y; Xu Z; Zhao J; Zhang X; Liu Y; Tian S; Qin Z; Feng J; Zhang F; Zhu J; Xu Y; Lou W; Ji Y; Zhao J; He F; Hou Y; Ding C
    J Hematol Oncol; 2022 Nov; 15(1):168. PubMed ID: 36434634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity.
    Moosavi SH; Eide PW; Eilertsen IA; Brunsell TH; Berg KCG; Røsok BI; Brudvik KW; Bjørnbeth BA; Guren MG; Nesbakken A; Lothe RA; Sveen A
    Genome Med; 2021 Sep; 13(1):143. PubMed ID: 34470666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways.
    Soltis AR; Bateman NW; Liu J; Nguyen T; Franks TJ; Zhang X; Dalgard CL; Viollet C; Somiari S; Yan C; Zeman K; Skinner WJ; Lee JSH; Pollard HB; Turner C; Petricoin EF; Meerzaman D; Conrads TP; Hu H; ; Shriver CD; Moskaluk CA; Browning RF; Wilkerson MD
    Cell Rep Med; 2022 Nov; 3(11):100819. PubMed ID: 36384096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-induced Nur77 activates PI3K/Akt signaling
    Shi Z; To SKY; Zhang S; Deng S; Artemenko M; Zhang M; Tang J; Zeng JZ; Wong AST
    Theranostics; 2021; 11(7):3376-3391. PubMed ID: 33537093
    [No Abstract]   [Full Text] [Related]  

  • 9. Proteome biology of primary colorectal carcinoma and corresponding liver metastases.
    Fahrner M; Bronsert P; Fichtner-Feigl S; Jud A; Schilling O
    Neoplasia; 2021 Dec; 23(12):1240-1251. PubMed ID: 34768110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
    Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
    BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
    Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.
    Berg KCG; Eide PW; Eilertsen IA; Johannessen B; Bruun J; Danielsen SA; Bjørnslett M; Meza-Zepeda LA; Eknæs M; Lind GE; Myklebost O; Skotheim RI; Sveen A; Lothe RA
    Mol Cancer; 2017 Jul; 16(1):116. PubMed ID: 28683746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-Depth Characterization of Mass Spectrometry-Based Proteomic Profiles Revealed Novel Signature Proteins Associated with Liver Metastatic Colorectal Cancers.
    Ku X; Xu Y; Cai C; Yang Y; Cui L; Yan W
    Anal Cell Pathol (Amst); 2019; 2019():7653230. PubMed ID: 31781478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteogenomic interrogation of cancer cell lines: an overview of the field.
    Tsang O; Wong JWH
    Expert Rev Proteomics; 2021 Mar; 18(3):221-232. PubMed ID: 33877947
    [No Abstract]   [Full Text] [Related]  

  • 15. Integrated Omics of Metastatic Colorectal Cancer.
    Li C; Sun YD; Yu GY; Cui JR; Lou Z; Zhang H; Huang Y; Bai CG; Deng LL; Liu P; Zheng K; Wang YH; Wang QQ; Li QR; Wu QQ; Liu Q; Shyr Y; Li YX; Chen LN; Wu JR; Zhang W; Zeng R
    Cancer Cell; 2020 Nov; 38(5):734-747.e9. PubMed ID: 32888432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and microenvironmental intra-tumor heterogeneity impacts colorectal cancer evolution and metastatic development.
    Sobral D; Martins M; Kaplan S; Golkaram M; Salmans M; Khan N; Vijayaraghavan R; Casimiro S; Fernandes A; Borralho P; Ferreira C; Pinto R; Abreu C; Costa AL; Zhang S; Pawlowski T; Godsey J; Mansinho A; Macedo D; Lobo-Martins S; Filipe P; Esteves R; Coutinho J; Costa PM; Ramires A; Aldeia F; Quintela A; So A; Liu L; Grosso AR; Costa L
    Commun Biol; 2022 Sep; 5(1):937. PubMed ID: 36085309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma.
    Gillette MA; Satpathy S; Cao S; Dhanasekaran SM; Vasaikar SV; Krug K; Petralia F; Li Y; Liang WW; Reva B; Krek A; Ji J; Song X; Liu W; Hong R; Yao L; Blumenberg L; Savage SR; Wendl MC; Wen B; Li K; Tang LC; MacMullan MA; Avanessian SC; Kane MH; Newton CJ; Cornwell M; Kothadia RB; Ma W; Yoo S; Mannan R; Vats P; Kumar-Sinha C; Kawaler EA; Omelchenko T; Colaprico A; Geffen Y; Maruvka YE; da Veiga Leprevost F; Wiznerowicz M; Gümüş ZH; Veluswamy RR; Hostetter G; Heiman DI; Wyczalkowski MA; Hiltke T; Mesri M; Kinsinger CR; Boja ES; Omenn GS; Chinnaiyan AM; Rodriguez H; Li QK; Jewell SD; Thiagarajan M; Getz G; Zhang B; Fenyö D; Ruggles KV; Cieslik MP; Robles AI; Clauser KR; Govindan R; Wang P; Nesvizhskii AI; Ding L; Mani DR; Carr SA;
    Cell; 2020 Jul; 182(1):200-225.e35. PubMed ID: 32649874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer.
    Dienstmann R; Salazar R; Tabernero J
    Am Soc Clin Oncol Educ Book; 2018 May; 38():231-238. PubMed ID: 30231342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteogenomic analysis of pancreatic cancer subtypes.
    Kafita D; Nkhoma P; Zulu M; Sinkala M
    PLoS One; 2021; 16(9):e0257084. PubMed ID: 34506537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival.
    Clarke CN; Lee MS; Wei W; Manyam G; Jiang ZQ; Lu Y; Morris J; Broom B; Menter D; Vilar-Sanchez E; Raghav K; Eng C; Chang GJ; Simon I; Bernards R; Overman M; Mills GB; Maru D; Kopetz S
    Ann Surg Oncol; 2017 Dec; 24(13):4051-4058. PubMed ID: 28936799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.